Literature DB >> 25815118

Cardiac disease modeling using induced pluripotent stem cell-derived human cardiomyocytes.

Patrizia Dell'Era1, Patrizia Benzoni1, Elisabetta Crescini1, Matteo Valle1, Er Xia1, Antonella Consiglio1, Maurizio Memo1.   

Abstract

Causative mutations and variants associated with cardiac diseases have been found in genes encoding cardiac ion channels, accessory proteins, cytoskeletal components, junctional proteins, and signaling molecules. In most cases the functional evaluation of the genetic alteration has been carried out by expressing the mutated proteins in in-vitro heterologous systems. While these studies have provided a wealth of functional details that have greatly enhanced the understanding of the pathological mechanisms, it has always been clear that heterologous expression of the mutant protein bears the intrinsic limitation of the lack of a proper intracellular environment and the lack of pathological remodeling. The results obtained from the application of the next generation sequencing technique to patients suffering from cardiac diseases have identified several loci, mostly in non-coding DNA regions, which still await functional analysis. The isolation and culture of human embryonic stem cells has initially provided a constant source of cells from which cardiomyocytes (CMs) can be obtained by differentiation. Furthermore, the possibility to reprogram cellular fate to a pluripotent state, has opened this process to the study of genetic diseases. Thus induced pluripotent stem cells (iPSCs) represent a completely new cellular model that overcomes the limitations of heterologous studies. Importantly, due to the possibility to keep spontaneously beating CMs in culture for several months, during which they show a certain degree of maturation/aging, this approach will also provide a system in which to address the effect of long-term expression of the mutated proteins or any other DNA mutation, in terms of electrophysiological remodeling. Moreover, since iPSC preserve the entire patients' genetic context, the system will help the physicians in identifying the most appropriate pharmacological intervention to correct the functional alteration. This article summarizes the current knowledge of cardiac genetic diseases modelled with iPSC.

Entities:  

Keywords:  Cardiac arrhythmias; Cardiomyopathies; Human cardiomyocytes; Induced pluripotent stem cells

Year:  2015        PMID: 25815118      PMCID: PMC4369490          DOI: 10.4252/wjsc.v7.i2.329

Source DB:  PubMed          Journal:  World J Stem Cells        ISSN: 1948-0210            Impact factor:   5.326


  93 in total

1.  Simple suspension culture system of human iPS cells maintaining their pluripotency for cardiac cell sheet engineering.

Authors:  Yuji Haraguchi; Katsuhisa Matsuura; Tatsuya Shimizu; Masayuki Yamato; Teruo Okano
Journal:  J Tissue Eng Regen Med       Date:  2013-06-03       Impact factor: 3.963

2.  Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Björn C Knollmann; Nagesh Chopra; Thinn Hlaing; Brandy Akin; Tao Yang; Kristen Ettensohn; Barbara E C Knollmann; Kenneth D Horton; Neil J Weissman; Izabela Holinstat; Wei Zhang; Dan M Roden; Larry R Jones; Clara Franzini-Armstrong; Karl Pfeifer
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

3.  Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines.

Authors:  Steven J Kattman; Alec D Witty; Mark Gagliardi; Nicole C Dubois; Maryam Niapour; Akitsu Hotta; James Ellis; Gordon Keller
Journal:  Cell Stem Cell       Date:  2011-02-04       Impact factor: 24.633

4.  Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy.

Authors:  Sharie B Parks; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Susan Ludwigsen; Amanda Peterson; Duanxiang Li; Petra Jakobs; Michael Litt; Charles B Porter; Peter S Rahko; Ray E Hershberger
Journal:  Am Heart J       Date:  2008-03-12       Impact factor: 4.749

5.  Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.

Authors:  Ashish Mehta; Glen Lester Sequiera; Chrishan J A Ramachandra; Yuliansa Sudibyo; Yingying Chung; Jingwei Sheng; Keng Yean Wong; Teng Hong Tan; Philip Wong; Reginald Liew; Winston Shim
Journal:  Cardiovasc Res       Date:  2014-03-12       Impact factor: 10.787

6.  Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype.

Authors:  Marina Cerrone; Xianming Lin; Mingliang Zhang; Esperanza Agullo-Pascual; Anna Pfenniger; Halina Chkourko Gusky; Valeria Novelli; Changsung Kim; Tiara Tirasawadichai; Daniel P Judge; Eli Rothenberg; Huei-Sheng Vincent Chen; Carlo Napolitano; Silvia G Priori; Mario Delmar
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

Review 7.  Congenital long QT syndrome.

Authors:  Lia Crotti; Giuseppe Celano; Federica Dagradi; Peter J Schwartz
Journal:  Orphanet J Rare Dis       Date:  2008-07-07       Impact factor: 4.123

8.  Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation.

Authors:  Atara Novak; Lili Barad; Naama Zeevi-Levin; Revital Shick; Ronit Shtrichman; Avraham Lorber; Joseph Itskovitz-Eldor; Ofer Binah
Journal:  J Cell Mol Med       Date:  2012-03       Impact factor: 5.310

Review 9.  Barth syndrome.

Authors:  Sarah L N Clarke; Ann Bowron; Iris L Gonzalez; Sarah J Groves; Ruth Newbury-Ecob; Nicol Clayton; Robin P Martin; Beverly Tsai-Goodman; Vanessa Garratt; Michael Ashworth; Valerie M Bowen; Katherine R McCurdy; Michaela K Damin; Carolyn T Spencer; Matthew J Toth; Richard I Kelley; Colin G Steward
Journal:  Orphanet J Rare Dis       Date:  2013-02-12       Impact factor: 4.123

10.  Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.

Authors:  Milena Bellin; Simona Casini; Richard P Davis; Cristina D'Aniello; Jessica Haas; Dorien Ward-van Oostwaard; Leon G J Tertoolen; Christian B Jung; David A Elliott; Andrea Welling; Karl-Ludwig Laugwitz; Alessandra Moretti; Christine L Mummery
Journal:  EMBO J       Date:  2013-11-08       Impact factor: 11.598

View more
  18 in total

1.  Inspiration from heart development: Biomimetic development of functional human cardiac organoids.

Authors:  Dylan J Richards; Robert C Coyle; Yu Tan; Jia Jia; Kerri Wong; Katelynn Toomer; Donald R Menick; Ying Mei
Journal:  Biomaterials       Date:  2017-07-12       Impact factor: 12.479

2.  A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.

Authors:  Hananeh Fonoudi; Hassan Ansari; Saeed Abbasalizadeh; Mehran Rezaei Larijani; Sahar Kiani; Shiva Hashemizadeh; Ali Sharifi Zarchi; Alexis Bosman; Gillian M Blue; Sara Pahlavan; Matthew Perry; Yishay Orr; Yaroslav Mayorchak; Jamie Vandenberg; Mahmood Talkhabi; David S Winlaw; Richard P Harvey; Nasser Aghdami; Hossein Baharvand
Journal:  Stem Cells Transl Med       Date:  2015-10-28       Impact factor: 6.940

Review 3.  High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.

Authors:  Juan C Del Álamo; Derek Lemons; Ricardo Serrano; Alex Savchenko; Fabio Cerignoli; Rolf Bodmer; Mark Mercola
Journal:  Biochim Biophys Acta       Date:  2016-03-04

Review 4.  In vitro cardiac tissue models: Current status and future prospects.

Authors:  Anurag Mathur; Zhen Ma; Peter Loskill; Shaheen Jeeawoody; Kevin E Healy
Journal:  Adv Drug Deliv Rev       Date:  2015-09-30       Impact factor: 15.470

5.  Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity.

Authors:  Dylan J Richards; Yang Li; Charles M Kerr; Jenny Yao; Gyda C Beeson; Robert C Coyle; Xun Chen; Jia Jia; Brooke Damon; Robert Wilson; E Starr Hazard; Gary Hardiman; Donald R Menick; Craig C Beeson; Hai Yao; Tong Ye; Ying Mei
Journal:  Nat Biomed Eng       Date:  2020-04-13       Impact factor: 25.671

6.  Calcium Transient Assays for Compound Screening with Human iPSC-derived Cardiomyocytes: Evaluating New Tools.

Authors:  Neil J Daily; Radleigh Santos; Joseph Vecchi; Pinar Kemanli; Tetsuro Wakatsuki
Journal:  J Evol Stem Cell Res       Date:  2017-01-24

Review 7.  Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.

Authors:  E Giacomelli; C L Mummery; M Bellin
Journal:  Cell Mol Life Sci       Date:  2017-06-01       Impact factor: 9.261

Review 8.  From iPSC towards cardiac tissue-a road under construction.

Authors:  Stefan Peischard; Ilaria Piccini; Nathalie Strutz-Seebohm; Boris Greber; Guiscard Seebohm
Journal:  Pflugers Arch       Date:  2017-06-01       Impact factor: 3.657

9.  Sodium channel current loss of function in induced pluripotent stem cell-derived cardiomyocytes from a Brugada syndrome patient.

Authors:  Elisabet Selga; Franziska Sendfeld; Rebecca Martinez-Moreno; Claire N Medine; Olga Tura-Ceide; Sir Ian Wilmut; Guillermo J Pérez; Fabiana S Scornik; Ramon Brugada; Nicholas L Mills
Journal:  J Mol Cell Cardiol       Date:  2017-10-09       Impact factor: 5.000

10.  The human somatostatin receptor type 2 as an imaging and suicide reporter gene for pluripotent stem cell-derived therapy of myocardial infarction.

Authors:  Katrien Neyrinck; Natacha Breuls; Bryan Holvoet; Wouter Oosterlinck; Esther Wolfs; Hubert Vanbilloen; Olivier Gheysens; Robin Duelen; Willy Gsell; Ivo Lambrichts; Uwe Himmelreich; Catherine M Verfaillie; Maurilio Sampaolesi; Christophe M Deroose
Journal:  Theranostics       Date:  2018-04-14       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.